We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-6.35%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.4B
AUM Growth
-$782M
Cap. Flow
+$157M
Cap. Flow %
1.38%
Top 10 Hldgs %
87.68%
Holding
124
New
6
Increased
21
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$234M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$100M
3
ASND icon
Ascendis Pharma A/S
ASND
+$10.6M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.37M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$6.88M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$69.3M
2
DERM
Dermira, Inc.
DERM
+$14.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.5M
4
EXEL icon
Exelixis
EXEL
+$11M
5
CERS icon
Cerus
CERS
+$9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.03%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABUS icon
101
Arbutus Biopharma
ABUS
$1.03B
$650K 0.01%
180,582
– –
CMRX
102
DELISTED
Chimerix, Inc.
CMRX
$628K 0.01%
115,216
– –
BDSI
103
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$588K 0.01%
210,021
– –
FPRX
104
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$580K 0.01%
19,247
– –
BIVV
105
DELISTED
Bioverativ Inc. Common Stock
BIVV
$496K ﹤0.01%
8,249
– –
CCXI
106
DELISTED
ChemoCentryx, Inc.
CCXI
$459K ﹤0.01%
49,064
– –
TARA icon
107
Protara Therapeutics
TARA
$228M
$455K ﹤0.01%
7,465
– –
ADAP
108
DELISTED
Adaptimmune Therapeutics
ADAP
$449K ﹤0.01%
100,000
– –
TMBR
109
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$287K ﹤0.01%
40
+15
+60% +$131K
AIXC
110
AIxCrypto Holdings Inc
AIXC
$22.7M
$220K ﹤0.01%
3
– –
TENX icon
111
Tenax Therapeutics
TENX
$65.5M
$98K ﹤0.01%
+4
New +$66.6K
BGMSP
112
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$82K ﹤0.01%
13,253
– –
BTX.WS
113
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$7K ﹤0.01%
20,084
– –
BIIB icon
114
Biogen
BIIB
$32B
– –
-16,500
Closed -$4.51M
ACOR
115
DELISTED
Acorda Therapeutics
ACOR
– –
-27,515
Closed -$69.3M
DERM
116
DELISTED
Dermira, Inc.
DERM
– –
-415,448
Closed -$14.2M
WINT
117
DELISTED
Windtree Therapeutics Inc
WINT
– –
-254,973
Closed -$291K
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2017 Portfolio in Review

As of Q2 2017, Julian Baker held 124 positions worth $11.4B, down 6.4% from $12.2B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Julian Baker's Q2 2017 filing shows 6 new, 21 increased, 9 reduced and 4 closed positions. Its largest new stake was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M. The largest sale was Acorda Therapeutics, an estimated $69.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q2 2017 buy was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M.
  • Julian Baker added most to Alexion Pharmaceuticals in Q2 2017, an estimated $234M increase.
  • Julian Baker's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $13.5M.
  • Julian Baker fully exited Acorda Therapeutics in Q2 2017, selling an estimated $69.3M.
  • Julian Baker's ten largest holdings make up 88% of its $11.4B portfolio in Q2 2017.
  • Julian Baker opened 6 new positions and closed 4 in Q2 2017.
  • Julian Baker's portfolio value fell 6.4% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.